Integra: Q3 Earnings Snapshot

Integra LifeSciences (IART) reported Q3 net income of $14.9M, or 19 cents per share, beating analyst estimates of 56 cents per share. Revenue was $411.2M, missing expectations of $414.5M. The company forecasts full-year earnings of $2.30-$2.40 per share and revenue of $1.63B-$1.65B.

Original reporting
Published Oct 21, 2026, 10:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integra: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$IARTNeutralMed
01

Why it matters

The earnings beat on a per‑share basis may attract short‑term buying, while the revenue shortfall could prompt caution.

02

Market read

First‑report earnings data for a mid‑cap med‑device company; relevant for traders monitoring earnings season.

03

What to watch

Guidance range remains broad; investors may focus on upcoming product pipeline and cost controls.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

Integra LifeSciences is a medical device maker listed on NASDAQ (IART). The article provides its Q3 earnings release.

Company-level read

Ticker impact

$IARTNeutralHigh confidence
Context

Integra LifeSciences reported Q3 earnings with EPS beat (59¢ vs 56¢ est) but revenue miss ($411.2M vs $414.5M est) and gave FY guidance of $2.30‑$2.40 EPS.

Expected impact

likely modest upside as market prices in the earnings beat, tempered by revenue miss

Evidence & confidence

First‑report earnings numbers provide new data; beat on earnings is a positive catalyst, but revenue miss introduces downside risk.

Market effects

Medical device sector may see mixed reaction as earnings beat offsets revenue weakness.

U.S. market participants will adjust expectations for Integra and comparable med‑device peers.

Limited to investors tracking U.S. med‑device stocks.

Counterpoint

Revenue miss could signal slowing demand, suggesting a pullback despite EPS beat.

Key entities

  • Integra LifeSciences Holdings Corp.

    Medical device manufacturer reporting Q3 results.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.